Downregulation of Brain Phosphodiesterase Type IV Measured with 11C-(R)-Rolipram Positron Emission Tomography in Major Depressive Disorder


      Phosphodiesterase type IV (PDE4), an important component of the cyclic adenosine monophosphate (cAMP) cascade, selectively metabolizes cAMP in the brain to the inactive monophosphate. Basic studies suggest that PDE4 mediates the effects of several antidepressants. This study sought to quantify the binding of 11C-(R)-rolipram, a PDE4 inhibitor, as an indirect measure of this enzyme's activity in the brain of individuals with major depressive disorder (MDD) compared with healthy control subjects.


      11C-(R)-Rolipram brain positron emission tomography scans were performed in 28 unmedicated MDD subjects and 25 age- and gender-matched healthy control subjects. Patients were moderately depressed and about one half were treatment-naive. 11C-(R)-Rolipram binding in the brain was measured using arterial 11C-(R)-rolipram levels to correct for the influence of cerebral blood flow.


      Major depressive disorder subjects showed a widespread, approximately 20% reduction in 11C-(R)-rolipram binding (p = .002), which was not caused by different volumes of gray matter. Decreased rolipram binding of similar magnitudes was observed in most brain areas. Rolipram binding did not correlate with the severity of depressive or anxiety symptoms.


      This study is the first to demonstrate that brain levels of PDE4, a critical enzyme that regulates cAMP, are decreased in unmedicated individuals with MDD in vivo. These results are in line with human postmortem and rodent studies demonstrating downregulation of the cAMP cascade in MDD and support the hypothesis that agents such as PDE4 inhibitors, which increase activity within the cAMP cascade, may have antidepressant effects.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cowburn R.F.
        • Marcusson J.O.
        • Eriksson A.
        • Wiehager B.
        • O'Neill C.
        Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims.
        Brain Res. 1994; 633: 297-304
        • Reiach J.S.
        • Li P.P.
        • Warsh J.J.
        • Kish S.J.
        • Young L.T.
        Reduced adenylyl cyclase immunolabeling and activity in postmortem temporal cortex of depressed suicide victims.
        J Affect Disord. 1999; 56: 141-151
        • Dwivedi Y.
        • Conley R.R.
        • Roberts R.C.
        • Tamminga C.A.
        • Pandey G.N.
        [3H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims.
        Am J Psychiatry. 2002; 159: 66-73
        • Dowlatshahi D.
        • MacQueen G.M.
        • Wang J.F.
        • Young L.T.
        Increased temporal cortex CREB concentrations and antidepressant treatment in major depression.
        Lancet. 1998; 352: 1754-1755
        • Dwivedi Y.
        • Rizavi H.S.
        • Conley R.R.
        • Roberts R.C.
        • Tamminga C.A.
        • Pandey G.N.
        Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects.
        Arch Gen Psychiatry. 2003; 60: 804-815
        • Duman R.S.
        • Malberg J.
        • Thome J.
        Neural plasticity to stress and antidepressant treatment.
        Biol Psychiatry. 1999; 46: 1181-1191
        • Houslay M.D.
        • Sullivan M.
        • Bolger G.B.
        The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions.
        in: August T.J. Murad F. Anders M.W. Coyle J.T. Advances in Pharmacology. Academic Press, London1998: 225-342
        • Ye Y.
        • Conti M.
        • Houslay M.D.
        • Farooqui S.M.
        • Chen M.
        • O'Donnell J.M.
        Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain.
        J Neurochem. 1997; 69: 2397-2404
        • Campos-Toimil M.
        • Keravis T.
        • Orallo F.
        • Takeda K.
        • Lugnier C.
        Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.
        Br J Pharmacol. 2008; 154: 82-92
        • Tsukada H.
        • Harada N.
        • Ohba H.
        • Nishiyama S.
        • Kakiuchi T.
        Facilitation of dopaminergic neural transmission does not affect [11C]SCH23390 binding to the striatal D1 dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D1 receptors: PET studies in the conscious monkey brain.
        Synapse. 2001; 42: 258-265
        • Hoffmann R.
        • Wilkinson I.R.
        • McCallum J.F.
        • Engels P.
        • Houslay M.D.
        cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: Generation of a molecular model.
        Biochem J. 1998; 333: 139-149
        • Itoh T.
        • Abe K.
        • Hong J.
        • Inoue O.
        • Pike V.W.
        • Innis R.B.
        • Fujita M.
        Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats.
        Synapse. 2010; 64: 172-176
        • First M.B.
        • Spitzer R.L.
        • Gibbon M.
        • Williams J.B.W.
        Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P).
        Biometrics Research Department, New York State Psychiatric Institute, New York2001
        • Montgomery S.A.
        • Asberg M.
        A new depression scale designed to be sensitive to change.
        Br J Psychiatry. 1979; 134: 382-389
        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Hamilton M.
        The assessment of anxiety states by rating.
        Br J Med Psychol. 1959; 32: 50-55
        • Zanotti-Fregonara P.
        • Zoghbi S.S.
        • Liow J.S.
        • Luong E.
        • Boellaard R.
        • Gladding R.L.
        • et al.
        Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: A retest study and use of an image-derived input function.
        Neuroimage. 2011; 54: 1903-1909
        • Innis R.B.
        • Cunningham V.J.
        • Delforge J.
        • Fujita M.
        • Gjedde A.
        • Gunn R.N.
        • et al.
        Consensus nomenclature for in vivo imaging of reversibly binding radioligands.
        J Cereb Blood Flow Metab. 2007; 27: 1533-1539
        • Logan J.
        • Fowler J.S.
        • Volkow N.D.
        • Wolf A.P.
        • Dewey S.L.
        • Schlyer D.J.
        • et al.
        Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)cocaine PET studies in human subjects.
        J Cereb Blood Flow Metab. 1990; 10: 740-747
        • Müller-Gätner H.W.
        • Links J.M.
        • Prince J.L.
        • Bryan R.N.
        • McVeigh E.
        • Leal J.P.
        • et al.
        Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects.
        J Cereb Blood Flow Metab. 1992; 12: 571-583
        • Carson R.E.
        Tracer kinetic modeling in PET.
        in: Valk P.E. Bailey D.L. Townsend D.W. Maisey M.N. Positron Emission Tomography Basic Science and Clinical Practice. Springer-Verlag, London2003
        • de Klerk O.L.
        • Willemsen A.T.
        • Roosink M.
        • Bartels A.L.
        • Hendrikse N.H.
        • Bosker F.J.
        • den Boer J.A.
        Locally increased P-glycoprotein function in major depression: A PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier.
        Int J Neuropsychopharmacol. 2009; 12: 895-904
        • Andersen P.H.
        • Klysner R.
        • Geisler A.
        Cyclic AMP phosphodiesterase activity in rat brain following chronic treatment with lithium, imipramine, reserpine, and combinations of lithium with imipramine or reserpine.
        Acta Pharmacol Toxicol (Copenh). 1983; 53: 337-343
        • Takahashi M.
        • Terwilliger R.
        • Lane C.
        • Mezes P.S.
        • Conti M.
        • Duman R.S.
        Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.
        J Neurosci. 1999; 19: 610-618
        • Fleischhacker W.W.
        • Hinterhuber H.
        • Bauer H.
        • Pflug B.
        • Berner P.
        • Simhandl C.
        • et al.
        A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder.
        Neuropsychobiology. 1992; 26: 59-64
        • Zhang H.T.
        Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs.
        Curr Pharm Des. 2009; 15: 1688-1698
        • O'Donnell J.M.
        • Zhang H.T.
        Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).
        Trends Pharmacol Sci. 2004; 25: 158-163
        • Li Y.F.
        • Cheng Y.F.
        • Huang Y.
        • Conti M.
        • Wilson S.P.
        • O'Donnell J.M.
        • Zhang H.T.
        Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.
        J Neurosci. 2011; 31: 172-183
        • Burgin A.B.
        • Magnusson O.T.
        • Singh J.
        • Witte P.
        • Staker B.L.
        • Bjornsson J.M.
        • et al.
        Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.
        Nat Biotechnol. 2010; 28: 63-70

      Linked Article

      • Evidence for Global Reduction in Brain Cyclic Adenosine Monophosphate Signaling in Depression
        Biological PsychiatryVol. 72Issue 7
        • Preview
          Fujita and coworkers, utilizing 11C-(R)-rolipram positron emission tomography, demonstrate that human subjects with major depression exhibit reductions in the enzyme phosphodiesterase-4 (PDE4) in a number of brain regions (1). PDE4, a cyclic adenosine monophosphate (AMP) phosphodiesterase, is an important regulator of cyclic AMP concentrations in the brain; it has been suggested as a molecular target for antidepressant drug discovery (2). The present study provides support for this premise and also suggests that global reductions in cyclic AMP signaling in the brain may be associated with major depression.
        • Full-Text
        • PDF